{"id":"danazol-twice-weekly","safety":{"commonSideEffects":[{"rate":null,"effect":"Virilization (acne, hirsutism, voice deepening)"},{"rate":null,"effect":"Menstrual irregularities"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Lipid abnormalities"},{"rate":null,"effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1479","moleculeType":"Small molecule","molecularWeight":"337.46"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Danazol acts as a weak androgen and inhibits the midcycle surge of luteinizing hormone and follicle-stimulating hormone, thereby suppressing ovulation and menstruation. It also has direct effects on immune function and fibrinolysis, making it useful in conditions characterized by excessive bleeding or immune-mediated pathology. The twice-weekly formulation represents a modified dosing schedule of the established danazol molecule.","oneSentence":"Danazol is a synthetic androgen that suppresses pituitary gonadotropins and has immunomodulatory effects, used to treat conditions involving abnormal bleeding or immune dysfunction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:31:01.304Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hereditary angioedema (HAE)"},{"name":"Endometriosis"},{"name":"Idiopathic thrombocytopenic purpura (ITP)"}]},"trialDetails":[{"nctId":"NCT00758953","phase":"PHASE2","title":"Pain Associated With Endometriosis","status":"COMPLETED","sponsor":"Lumara Health, Inc.","startDate":"2007-02","conditions":"Endometriosis","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Danazol Twice Weekly","genericName":"Danazol Twice Weekly","companyName":"Lumara Health, Inc.","companyId":"lumara-health-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Danazol is a synthetic androgen that suppresses pituitary gonadotropins and has immunomodulatory effects, used to treat conditions involving abnormal bleeding or immune dysfunction. Used for Hereditary angioedema (HAE), Endometriosis, Idiopathic thrombocytopenic purpura (ITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}